EDAP TMS EDAP 深 沪
等待开盘 09-16 09:30:00 美东时间
4.32
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 4.32
- 总市值 1.62亿
- 52周最高 5.05
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.21
- 委 比 0.00%
- 总股本 3748.20万
- 历史最高 12.65
- 量 比 0
- 振 幅 0.00%
- 历史最低 1.15
- 每 手 1
- 风险率 0.87%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多HC Wainwright & Co. Reiterates Buy on Edap TMS, Maintains $10 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Edap TMS (NASDAQ:FOCL) with a Buy and maintains $10 price target.
08-25 19:54
FocalTherics Completes ADS Offering, Boosting Capital Strength
FocalTherics ( ($FOCL) ) has shared an announcement. On August 11, 2026, EDAP T...
08-19 18:48
FocalTherics announces public ADS offering
FocalTherics (FOCL) has commenced an underwritten public offering of ADSs, with all shares to be sold by the company. The company expects to grant underwriters a 30-day option to purchase up to an add...
08-12 04:28
EDAP TMS pivots to pure-play robotic focal therapy
EDAP TMS ( ($EDAP) ) has provided an announcement. On June 1, 2026, FocalTheric...
06-02 05:00
EDAP To Change Name To FocalTherics With Strategic Shift To High-Growth Robotic Focal Therapy; Will Trade Under Symbol FOCL From June 1
The Company also announced its intention to report and classify its Extracorporeal Shock Wave Lithotripsy ("ESWL") and Distribution operating segments as discontinued operations in the Company's financial statements
05-29 19:34
Telix Pharma Enters Into LOI To Pursue Collaborations With EDAP And Profound Medical To Explore Investigational Use Of Telix's PSMA-PET1 Imaging Agents Gozellix And Illuccix With Robotic HIFU, And Other Image-Guided Therapies To Treat Prostate Cancer
Telix to partner with companies developing advanced minimally invasive and image-guided ablative technologies for prostate cancer.Initial focus on patient selection, treatment planning and post-treatment monitoring;
05-15 18:33
EDAP shares are trading higher after the company reported better-than-expected Q1 sales results.
EDAP shares are trading higher after the company reported better-than-expected ...
05-08 02:18
Edap TMS Sees FY2026 Sales $72.000M-$80.000M vs $74.601M Est.
Edap TMS (NASDAQ:EDAP) sees FY2026 sales of $72.000 million-$80.000 million vs $74.601 million analyst estimate.
05-07 19:36
Edap TMS Q1 EPS $(0.24) Misses $(0.22) Estimate, Sales $17.812M Beat $16.570M Estimate.
Edap TMS (NASDAQ:EDAP) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.22) by 9.09 percent. This is a 20 percent decrease over losses of $(0.20) per share from the same
05-07 19:33
